In a major boost to global tuberculosis (TB) diagnostics, the Serum Institute of India Pvt. Ltd. (SIIPL), through its UK-based subsidiary Serum Life Sciences Ltd., announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for SIILTIBCY®, a next-generation skin test designed to detect infection caused by Mycobacterium tuberculosis.
This authorization allows SIILTIBCY® to be used across the United Kingdom for adults and children, marking an important step toward more accurate and reliable TB detection.